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Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in
scleroderma is progressive development of ﬁbrous tissue and obliteration of the microvasculature. Currently, there are no medical
products for the treatment of scleroderma that provide both suﬃcient immunosuppression and low-risk side safety proﬁle with
negligible side eﬀects. There are a large number of experimental data showing that intravenous immunoglobulin (IVIG) has
multiple clinical and morphological eﬀects. On the other hand, some authors report good eﬀect of intravenous immune globulins
inpatientswithscleroderma.ThelessfrequentsideeﬀectsofIVIGindosesbeloworequalto2g/kg/monthdividedin5consecutive
days make IVIG a promising treatment of choice in scleroderma.
In 1981, the Swiss physician Paul Imbach prescribed IVIG
to a child with immune deﬁciency combined with idio-
pathic thrombocytopenic purpura (ITP). He was surprised
that, besides the increase in serum IgG levels, a dramatic
improvement in the platelet count was observed. By the
middle 1980s, such increase in platelet count in autoimmune
thrombocytopenia after the administration of IVIG had
been observed by many authors and IVIG were included in
the standard treatment for ITP. Moreover, the indications
for IVIG were broadened, and these preparations were
administered in a wide range of diseases.
Rationale for the Use of IVIG
(1) IVIG has immunomodulatory action.
(2) IVIG contains idiotypes that neutralize diﬀerent
autoantibodies.
(3) IVIG blocks the Fc receptors on the surface of B-cells
and macrophages.
(4) IVIG inhibits inﬂammatory mediators, such as cy-
tokines, chemokines, and metalloproteinases.
(5) IVIG neutralizes toxins.
(6) IVIG reduces immune complexes.
(7) Substitutive treatment in immune deﬁciencies.
(8) Alternative treatment, for example, in cases where all
other immunosuppressive therapeutic modalities
have shown to be ineﬃcient (ultima ratio).
Food and Drug Administration (FDA) has licensed the
administration of IVIG for the following six therapeutic
indications:
(1) treatment of primary immune deﬁciencies;
(2) prevention of infectious complications in patients
with chronic B-cell lymphatic leukemia and hypo-
gammaglobulinemia;
(3) prevention of coronary aneurism in Kawasaki’s dis-
ease;
(4) preventionofinfectionsandgraft-versus-hostdisease
after bone marrow transplantation;
(5) minimization of the risk for severe bacterial infec-
tions in children with HIV-infection;
(6) increasing of the platelet count and prevention of
hemorrhages in patients with ITP.2 International Journal of Rheumatology
Table 1: IVIG in patients with SSc.
Author/year Number of
patients Skin lesions Results Remarks
Bodemer et al. 1990 [6] 1 Only in the face Myositis improvement SSc-dermatomyositis
overlap
Levy et al. 2000 [8] 3 dcSSc Regression of skin score,
disease stabilization
No changes in PM-Scl
antibodies
Levy et al. 2004 [9]1 5 5 patients-lcSSc,
10 patients-dcSSc
Decreased mRSS, changes
in HAQ score
Very high skin score in
patients with lcSSc
Nacci et al. 2007 [10]7 5 patients-limited SSc,
2 patients diﬀuse SSc
Decreased VAS, IAFD,
mRSS after 6-month
treatment
Eﬀects on joints and skin
Asano et al. 2005 [11]1
Fingers, hands, forearms,
upper arms, face, chest,
abdomen, lower legs,
dorsum of the feet
Decreased mRSS
Szekanecz et al. 2009 [12]1 Disuse SSc, refractory to
treatment Good clinical eﬀect Combination of IVIG and
plasmapheresis
Indermatology,IVIGisusedmainlyinpatientswithder-
matomyositis and polymyositis [1, 2] and with autoimmune
bullous dermatoses [3–5]. Recently, beneﬁcial eﬀect in small
series of patients with diﬀerent forms of scleroderma has
been reported by some authors.
Scleroderma is progressive autoimmune disease associ-
ated with severe disability. It is manifested as diﬀuse cuta-
neous (dcSSc), limited cutaneous (lcSSc), or disease with
multisystemic and multiorgan involvement (SSc). The major
underlying pathological process in scleroderma is progres-
sive development of ﬁbrous tissue and obliteration of the
microvasculature. Currently, there is no speciﬁc medicinal
treatment of scleroderma that could provide both suﬃ-
cient immunosuppression and low-risk side safety proﬁle
with negligible side eﬀects. Several cytotoxic and immun-
omodulatory agents are used for the treatment of sclero-
derma, including cyclophosphamide, mycophenolate mofet-
il, cyclosporine, and, more recently, selective inhibitors of
the T-(Sirolimus, Alefacept) and B-cells (Rituximab), anti-
ﬁbrotic agents (Imatinib), and hematopoietic stem cell
transplantation.
In 1990, Bodemer et al. report the beneﬁcial eﬀect of
IVIG 2g/kg/month combined with prednisone for 10
months in patients with SSc-dermatomyositis overlap [6].
They point that the skin lesions are only on the face and
the improvement after IVIG concerns only the myositis
(Table 1). In 1998, Wollina et al. reported the beneﬁcial
eﬀect of IVIG on the satellite infection in a patient with
disabling morphea [7]. In 2000, Levy et al. report the
beneﬁcial eﬀects of IVIG 2g/kg/month in three patients
with SSc [8]. All of them had past history for progressive
and rapidly deteriorating skin symptoms not responsible
to previous therapy with colchicine and one of them—
colchicne and D-penicillamine. Two of the patients had been
treated for 6 months without side eﬀects, and, in the third
patient, the treatment was ceased after month 3 due to
renal damage and subsequent sepsis. In all three patients,
regression in the skin score and disease stabilization were
observed, but the levels of PM-Scl antibodies measured by
indirect immunoﬂuorescence test showed no changes during
treatment (Table 1). Discussing these data, the authors point
that “three patients are insuﬃcient to evaluate a novel
therapy.” They assume that future studies are needed to show
the eﬀect of IVIG on scleroderma.
In 2004, a research group from the Sheba Medical Center
and the University of Florence [9] reported 15 patients with
SSc (5 with lcSSc and 10 with dcSSc) treated with IVIG
2g/kg/month(Table 1). Eleven patients had been treated for
6 months, three for 4 months, and one patient for 3 months.
In all patients, the skin involvement was evaluated using
the modiﬁed Rodnan skin score (mRSS) at baseline and
after the completion of treatment. Eight patients completed
the Health Assessment Questionnaire (HAQ). The mean
mRSS after therapy with IVIG was signiﬁcantly decreased:
shorterdiseasedurationwasassociatedwithmilderdegreeof
improvement (21% in mRSS), longer disease duration (≥2
years)—44% in mRSS. Moreover, the HAQ score revealed
that the patients report marked improvement. The authors
assume that suppressing the action of proﬁbrotic cytokines
(IL-4, TGF beta) IVIG may improve the disease and quality
of life of patients with SSc.
Several years later in a pilot study, the same authors
reported marked improvement in articular involvement in
seven Caucasian patients with severe refractive arthropathy
in SSc (ﬁve with localized and 2 with diﬀuse systemic scle-
rosis) treated with IVIG 2g/kg/month during 4 days/month
for six consecutive courses [10]. The authors evaluated the
eﬀect of the treatment upon the following symptoms: joint
tendernessandswellingandarticulardeformities.Atbaseline
and after six-month treatment, the patients underwent
the following tests: Ritchie Index (RI) evaluation of artic-
ular involvement; Dreiser Algo-Functional Index (IAFD)
evaluation of hand joint function; pain visual analogue
scale (VAS) to measure joint pain; HAQ to evaluate the
limitations in everyday living and physical disability; mRSS
for evaluation of skin involvement. After six-month therapy
with IVIG in 6/7 patients VAS, IAFD and mRSS decreased
signiﬁcantly and HAQ score showed improvement in generalInternational Journal of Rheumatology 3
functionality(Table 1).Accordingtotheauthors,thetherapy
with IVIG may be useful for SSc patients with severe joint
involvementandthosewhoarerefractorytoothertreatment.
In 2005, Asano et al. reported similar results in a 60-
years-old female Japanese patient with diﬀuse scleroderma
treated with IVIG 400mg/kg for 5 consecutive days [11]. The
patient’s condition improved dramatically with signiﬁcant
decrease in mRSS and marked improvement on the histo-
logical examination (Table 1).
In 2009, Szekanecz et al. reported a case of diﬀuse
SSc without response to conventional therapy. After 12
months of combined repeated treatment with IVIG and
plasmapheresis, they administered a good clinical eﬀect [12].
There is a large number of experimental data showing
that IVIG has multiple clinical and morphological eﬀects.
For instance, the administration of IVIG 2g/kg in tight-skin
mouse leads to signiﬁcant decreases in collagen depositions
and reduction of type I collagen gene expression [13].
It has been speculated that the overproduction of ﬁbrotic
tissue in SSc is due to the increased expression of TGFβ1
and IL-4 [14, 15]. The experimental studies of Blank et al.
in tight-skin mice (animal model of SSc) revealed that the
administration of IVIG in total dose 2g/kg for four weeks
lead to marked decrease in collagen deposition and reduc-
tion in type I collagen gene expression [13]. The authors
observed parallel inhibition of TGFβ1 and IL-4 secretion by
splenocytes with no changes in IFNγ levels. The studies of
Asano et al. [11] revealed that the ﬁbroblasts of scleroderma
patients contain more type I procollagen, TGFβ and α-
smooth muscle actin, and less matrix metalloproteinase 1.
After the administration of IVIG the initial abnormalities
normalize. Amemiya et al. [16] speculate that in inﬂam-
matory myopathies IVIG can bind directly to TGFβ.O n
the other hand, IVIG downregulate T cells with subsequent
decrease in ﬁbroblast TGFβ production. Other possible
explanations of the beneﬁcial eﬀect of IVIG in reducing of
ﬁbrosis include inhibition of complement cascade, presence
of anti-Fas antibodies in IVIG preparations that inhibit
ﬁbrogenesis by blocking the activity of Fas, and presence of
antiﬁbroblast antibodies that inhibit ﬁbrogenesis [17]. These
experimental data conﬁrm the hypothesis that the treatment
with IVIG in patients with diﬀerent forms of scleroderma
could change the ﬁbroblast phenotype in this disease.
There are not so many studies about the eﬀect of IVIG in
SSc patients. We found only several publications, of which
mainly case reports discussing the beneﬁcial eﬀect of this
treatment in SSc. On the other hand, the less frequent side
eﬀects of IVIG in doses below or equal to 2g/kg/month
divided in 5 consecutive days make IVIG a promising
treatment of choice in patients with scleroderma refractory
to other therapy. The current use of IVIG in dermatology is
at a rise, and this demands for new controlled clinical studies
in diﬀerent autoimmune skin diseases including SSc.
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